GHK-Cu Copper Peptide: Research Overview & UK Guide

GHK-Cu copper peptide is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) bound to a copper ion. It was first isolated from human plasma by the biochemist Loren Pickart in 1973 and has since been studied for its effects on collagen synthesis, wound remodelling, hair follicle biology and gene expression. In the UK it is sold as a research chemical for laboratory use only, and it has no MHRA marketing authorisation as a medicine.

This guide summarises what the published literature says about GHK-Cu, where the evidence is strong and where it is thin, how it differs from the cosmetic copper peptides you see in skincare, and what UK researchers should look for when buying it.

What is GHK-Cu copper peptide?

GHK is a short chain of three amino acids: glycine, histidine and lysine. On its own it has a very high affinity for copper(II), and in the body it is usually found as the GHK-Cu complex. Pickart's original observation was that plasma from younger donors kept liver cells behaving in a more youthful way than plasma from older donors, and he traced the active factor to this tripeptide.

Plasma concentrations of GHK are frequently quoted as falling from roughly 200 ng/mL in a person's twenties to around 80 ng/mL by their sixties. That age-related decline is one reason the peptide attracted interest from researchers working on tissue repair and skin ageing, although the figure comes from a small number of older assays and should be read as approximate.

GHK-Cu is often labelled copper tripeptide-1 in cosmetic ingredient lists. The molecule is the same, but the concentration, purity and delivery in a face cream are very different from the freeze-dried or solution-form material supplied for laboratory research.

What the research says

The most-cited modern review is Pickart and Margolina's 2018 paper in the International Journal of Molecular Sciences, 'Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data'. Drawing on the Broad Institute's Connectivity Map, the authors reported that GHK altered the expression of a large proportion of human genes in the dataset, with signals in pathways linked to tissue repair, antioxidant defence and inflammation.

In cell and animal models, GHK-Cu has been reported to stimulate collagen and glycosaminoglycan synthesis by fibroblasts, to modulate matrix metalloproteinases and their inhibitors, and to promote angiogenesis. A frequently referenced rat study found that ischaemic open wounds treated with GHK-Cu closed faster and showed lower levels of MMP-2, MMP-9 and TNF-beta than controls. Mouse studies have described increased hair follicle size and number around wound margins.

Human data is narrower. The controlled trials that exist are almost entirely topical: small studies of copper peptide creams reporting improvements in skin density, fine lines and photodamage over 8 to 12 weeks. A 2026 clinical trial registration (NCT07437586) is investigating a topical GHK-Cu gel for acute skin wound healing. There are no large published randomised trials of injectable GHK-Cu in humans, and a September 2026 NPR feature noted that the move from creams to injections has run ahead of the science.

GHK-Cu research areas compared

The table below summarises the main areas in which GHK-Cu has been investigated and the type of evidence that supports each. It is intended as a map of the literature, not a statement of effect.

How GHK-Cu is used in laboratory research

In a research setting, GHK-Cu is typically studied in cell culture (fibroblasts, keratinocytes and endothelial cells), in ex vivo skin explants, and in animal wound models. Because the copper ion is part of the active complex, researchers pay attention to copper loading, chelation by buffer components and the stability of the complex in solution.

• Cell-based assays measuring collagen output, MMP activity and gene expression after exposure to GHK-Cu.
• Combination studies pairing GHK-Cu with other repair peptides such as BPC-157 and TB-500 (thymosin beta-4 fragment), which is the rationale behind blended research pens.
• Formulation research on delivery vehicles, including microneedle patches and hydrogels, where GHK-Cu's blue colour makes it easy to track visually.
• Stability testing, since GHK-Cu solutions are sensitive to light and to oxidising conditions.

Single GHK-Cu vs blended research pens

Researchers can buy GHK-Cu on its own or as part of a multi-peptide blend. A single-compound pen, such as a 100mg GHK-Cu pen, is the right choice when the study design needs to isolate the effect of one variable. Blends are used where the research question is about combined or synergistic activity.

Calibre's Glow pen combines 50mg GHK-Cu with 10mg TB4 and 10mg BPC-157; the Klow pen adds 10mg of KPV, a tripeptide fragment of alpha-MSH that has been studied for its anti-inflammatory properties. These combinations reflect the compounds most often investigated together in skin and tissue-repair research, but a blend is only useful if you know the exact quantity of each component, which is why the certificate of analysis matters.

Is GHK-Cu legal in the UK?

Yes. GHK-Cu is legal to buy, sell and possess in the UK as a research chemical. It is not a controlled substance under the Misuse of Drugs Act 1971 and it is not on the UK's psychoactive substances list. Cosmetic-grade copper peptides are also legal in topical products under UK cosmetics regulation.

What is not lawful is supplying GHK-Cu for human medicinal use, or marketing it with medicinal claims, without a marketing authorisation from the MHRA. GHK-Cu has no such authorisation. That is why reputable UK suppliers sell it strictly for research and why this article describes findings from the literature rather than making claims about any product.

What to check before you buy GHK-Cu in the UK

GHK-Cu is relatively cheap to synthesise, which means the market is crowded and quality varies. The peptide should be a distinctive blue in solution because of the copper complex; a colourless or grey product suggests the copper has not been properly loaded or the material has degraded. Colour alone, though, is not proof of purity.

1. Ask for a batch-specific certificate of analysis. Calibre pens are tested by Janoshik Analytical and the COAs are published on the site's COA page.
2. Check that purity is measured by HPLC and identity confirmed by mass spectrometry, with a target above 99%.
3. Confirm the stated quantity is the peptide content, not the gross weight of the vial or pen.
4. Look for pre-filled, precision-made pens if your workflow benefits from consistent, ready-to-use volumes rather than reconstituting lyophilised powder.
5. Store GHK-Cu away from light and heat; the copper complex is more stable than free GHK but still degrades if mishandled.

Summary

GHK-Cu copper peptide is one of the better-characterised research peptides, with fifty years of literature behind it and a plausible mechanism grounded in copper delivery and gene modulation. The strongest evidence is in cells and animals; human data is limited to small topical trials. For UK researchers it is legal to buy as a research chemical, provided it is sourced with a proper certificate of analysis and used strictly for laboratory work.